Beijing Mabworks Biotech Co., Ltd.

This study tests a drug called MIL62 in 102 adults with NMOSD, a rare autoimmune disease that attacks the optic nerves and spinal cord. The goal is to see if MIL62 can safely prevent relapses (sudden worsening of symptoms). Participants receive MIL62 and are monitored for side ef…

This study tests a new drug called MIL62 in 120 adults with active systemic lupus erythematosus (SLE), an autoimmune disease. The goal is to see if MIL62 can reduce disease activity better than a placebo over 12 weeks, with long-term follow-up up to 76 weeks. Participants must ha…